Table 1 Main characteristics extracted from the selected studies
First author, Date | Country | Study design | biological source | Number of patients | Cut Off | MiRNA type | MiRNA expression | HR of deregulated miRNA expression (OS, DSS, DFS, RFS, PFS) |
|---|---|---|---|---|---|---|---|---|
Jia(2013) | China | RT | Tissue | 81 | Median | miR-195 | Downregulation | OS: HR,1.98 (1.28–3.31) |
Supic(2018) | Serbia | RT | Tissue | 60 | ROC analysis, Cutoff = 2.407 | miR-183, miR-21 | Upregulation | miR-183-OS: HR,5.666(1.708–18.791) miR-21-OS: HR,2.002 (0.904–4.434) miR-183-RFS: HR,1.868(0.924–3.776) |
Zheng(2016) | China | RT | Tissue | 72 | Score ≥ 2 | miR-21 | Upregulation | OS: HR,1.32 (1.09–2.56) |
Jia(2014) | China | RT | Tissue | 76 | Tertile | miR-26a | Downregulation | OS: HR,2.74 (1.44–5.21) |
Li (2009) | China | RT | Tissue | 103 | Median | miR-21 | Upregulation | OS: HR, 2.06 (1.21–3.51) |
Kawakita(2014) | Japan | RT | Tissue | 79 | Score ≥ 1 | miR-21 | Upregulation | DSS: HR, 1.19 (0.71–1.9) |
Maruyama(2018) | Japan | RT | Tissue | 50 | Median | miR-196a-5p | Upregulation | OS: HR, 1.01(1.21–5.19); DFS: HR, 3.06 (1.32–7.12) |
Xie(2016) | China | RT | Tissue | 100 | Score ≥ 1 | miR-320a | Downregulation | OS: HR,1.98(0.939–3.04) |
Berania(2017) | Canada | RT | Tissue | 58 | median | miR-18a, miR-548b | miR-18a-Upregulation miR-548b-Downregulation | miR-18a-OS: HR,4.20(1.55–13.23) miR-18a-PFS: HR,6.89 (1.97–29.86) miR-548b-OS: HR,3.55(1.42–10.82) |
Jia(2015) | China | RT | Tissue | 105 | median | miR-375 | Downregulation | OS: HR,2.01(1.20–3.36) |
W. Chen(2019) | China | RT | Tissue | 126 | median | miR-5787 | Downregulation | OS: HR,1.976(1.359–2.873) |
S. Chen(2019) | China | RT | Tissue | 60 | median | miR-611 | Upregulation | OS: HR,2.19(0.92–5.18) |